We maintain our MARKET PERFORM rating on TCM with a projected TSR of 5.7%, despite raising our target price (TP) 16.8%, as TCM’s stock price has risen 13.0% in the last three months. Our revised TP reflects an increase in our recurring NPAT 2017-2023F CAG